Something has got to give: funding innovation in an era of rigid budgeting, and why physicians should care

Ana Barradas-Pires^{1

2}, Mario DiazNuila Alcazar^{2

3}, Antoni Martínez-Rubio^{2

3}, Konstantinos Dimopoulos^{1

4}

Affiliations

¹ Department of Cardiology, Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, Sydney Street, Chelsea, London SW3 6NP, UK.
² Autonomous University of Barcelona, Barcelona, Spain.
³ Department of Cardiology, University Hospital Parc Tauli, Sabadell, Spain.
⁴ National Heart & Lung Institute, Imperial College London, London, UK.

Editorial

Ana Barradas-Pires et al. Eur J Prev Cardiol. 2021.

. 2021 Mar 23;28(1):44-46.

doi: 10.1093/eurjpc/zwaa140.

Ana Barradas-Pires^{1

2}, Mario DiazNuila Alcazar^{2

3}, Antoni Martínez-Rubio^{2

3}, Konstantinos Dimopoulos^{1

4}

¹ Department of Cardiology, Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, Sydney Street, Chelsea, London SW3 6NP, UK.
² Autonomous University of Barcelona, Barcelona, Spain.
³ Department of Cardiology, University Hospital Parc Tauli, Sabadell, Spain.
⁴ National Heart & Lung Institute, Imperial College London, London, UK.

No abstract available

Comment on

The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort.
Blaum C, Seiffert M, Goßling A, Kröger F, Bay B, Lorenz T, Braetz J, Graef A, Zeller T, Schnabel R, Clemmensen P, Westermann D, Blankenberg S, Brunner FJ, Waldeyer C. Blaum C, et al. Eur J Prev Cardiol. 2021 Mar 23;28(1):47-56. doi: 10.1093/eurjpc/zwaa088. Eur J Prev Cardiol. 2021. PMID: 33580772